AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

AngioDynamics, Inc. ANGO recently received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System. The system is an off-circuit, multi-purpose mechanical aspiration thrombectomy device that will be utilized in the non-surgical removal of thrombi or emboli from the vasculature.

Notably, the company expects to commercially release the AlphaVac System in the second half of 2021.

Concurrently, the company also announced that it will report its fiscal fourth-quarter 2021 results on Jul 13, before the opening bell.

This clearance is likely to boost AngioDynamics’ peripheral vascular product portfolio.

More on the News

AngioDynamics is a market leading provider of minimally invasive medical devices used for vascular access, surgery, peripheral vascular disease and oncology. The receipt of this clearance will enable the company to enhance its broad product line and bolster its customer reach.

Zacks Investment ResearchImage Source: Zacks Investment Research

The clearance of the AlphaVac System is likely to result in better patient outcomes, thereby highlighting the importance of the company’s focused internal research and development activities.

Market Prospects

Per a report by MarketsandMarkets, the global thrombectomy devices market is anticipated to reach $1.45 billion by 2022, witnessing a CAGR of 6.7% during the forecast period. Growing number of minimally invasive procedures, rising target patient population, increase in demand for minimally invasive thrombectomy procedures and ongoing technological advancements are some crucial factors driving this market’s growth.

Hence, the approval is well-timed for AngioDynamics.

Notable Developments

The company’s fiscal third-quarter 2021 procedure volumes remained solid for the company’s AngioVac platform with revenues climbing 27% year over year.

In November 2020, the company announced the safety and efficiency outcomes from the Registry of AngioVac System Procedures In Detail (RAPID) database. The study proved that the AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses across a wide array of patient populations.

Price Performance

Shares of this Zacks Rank #3 (Hold) company have surged 63.4% on a year-to-date basis against the industry’s decline of 4%.

Stocks to Consider

Some better-ranked stocks from the broader medical space are HCA Healthcare, Inc. HCA, DaVita Inc. DVA and Encompass Health Corporation EHC, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

HCA Healthcare’s long-term earnings growth rate is expected at 12.3%.

DaVita’s long-term earnings growth rate is estimated at 14.4%.

Encompass Health’s long-term earnings growth rate is projected at 17.3%.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Click to get this free report

AngioDynamics, Inc. (ANGO): Free Stock Analysis Report

DaVita Inc. (DVA): Free Stock Analysis Report

HCA Healthcare, Inc. (HCA): Free Stock Analysis Report

Encompass Health Corporation (EHC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Stocks Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More